Canadian investigator has been honoured for his exceptional achievements at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Paris, France
Professor Jonathan D. Adachi has been awarded the prestigious Herbert A. Fleisch ESCEO-IOF Medal at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. The Medal is named after the late Professor Herbert A. Fleisch, a renowned investigator whose groundbreaking work contributed to the development of the field of scientific knowledge about metabolic bone diseases and their treatment. It is awarded annually by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) to a researcher who has made outstanding achievements in bone and osteoporosis research.
Presenting the Medal at a special award ceremony held on April 5, 2019, Professor René Rizzoli, Chair of the ESCEO Scientific Advisory Board, stated:
“It is an honour to present this Award to Jonathan (Rick) Adachi, a highly respected physician and investigator in the bone field. Professor Adachi’s epidemiological research and clinical studies have advanced knowledge about risk factors and therapies for osteoporosis. He has also made notable contributions to the development of clinical guidelines and is an internationally recognized educator and advocate on behalf of osteoporosis and fracture prevention in Canada, and around the world.”
Dr Jonathan Adachi is a Professor of Medicine at the Michael G. DeGroote School of Medicine at McMaster University. He is the Actavis Chair for Better Bone Health in Rheumatology. Dr Adachi has been involved in clinical trials and epidemiologic research, as well as imaging research in osteoporosis, osteoarthritis and rheumatoid arthritis examining a number of different imaging techniques including, peripheral quantitative computed tomography (pQCT), high resolution quantitative computed tomography (HRpQCT), peripheral magnetic resonance imaging (pMRI) and dual energy x-ray absorptiometry (DEXA). He has been a co-investigator in the CIHR funded Canadian Multicentre Osteoporosis Study (CaMOS), a 20-year, 10.000 subject epidemiologic study examining risk factors for bone loss and in establishing normal bone mineral density values in men and women and in premenopausal, peri-menopausal and postmenopausal women. He holds a separate CIHR grant examining pQCT, HRpQCT and pMRI images of bone structure and strength and will determine the relationship of bone structure and muscle to fractures in a subset of CaMOS subjects. In addition to these CIHR CaMOS funded grants, he is a co-investigator in a cross Canada study of pQCT in determining normal range for bone and muscle density and its relationship to muscle function using mechanography in 5000 individuals ranging from age 5 to age 75 years. Risk factors for fracture and the development of frailty at various ages will be examined. Dr Adachi has over 500 peer reviewed publications and is a respected leader in bone research in Canada and Internationally. He was awarded the Lindy Fraser Award by Osteoporosis Canada. In 2006, he received the North American Menopause Society award for Innovation in Osteoporosis Research. In 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for his work in osteoporosis and in 2014 he received the International Osteoporosis Foundation’s Olof Johnell Science Award for his contributions to the field of osteoporosis.
In addition to his scientific contributions he has been recognized by his peers for his clinical work and his contributions to his university. He was named consultant of the year in 2016 awarded by the Department of Family Medicine at St Joseph’s Healthcare. In 2017 he was awarded the William G. Bensen Distinguished Faculty Award for career service to the Michael G. DeGroote School of Medicine and the Faculty of Health Sciences, professional achievements through successes in his career path, and service to society including faculty, students, staff and patients.
World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Paris 2019):
Held jointly by IOF and ESCEO, the Congress took place in Paris, France from April 4-7, 2019. WCO-IOF-ESCEO is the world’s largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. For more information and to view congress abstracts visit http://www.
The International Osteoporosis Foundation (IOF) is the world’s largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as more than 240 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. http://www.
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. http://www.